AbbVie Inc. has returned its rights to a MerTK inhibitor program licensed from originator Dong-A ST well over four years ago, marking a setback for the leading South Korean pharma firm’s plan to step up its novel immuno-oncology R&D.
Dong-A ST, an affiliate of Dong-A Socio Holdings , said in a stock market disclosure that it would retain the $40m upfront payment from the two firms' original deal reached in 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?